MedTrace Logo

MRI Exploration of Meningeal Inflammatory Disease

NCT04707170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 302

Last updated 2023-12-13

No results posted yet for this study

Summary

Patients who have agreed to participate in the study will complete the MRI protocol as part of routine care, to which two additional sequences of 6 minutes duration will be added.

The MRI of routine care includes at least the following sequences:

* 3D T1 TFE 1.0 isotropic (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR pre-injection (opt) (3 minutes)
* 3D FLAIR post-injection (3 minutes)

As part of the research, the following sequences will be acquired:

* FABIR pre-injection (3 minutes)
* FABIR post-injection (3 minutes)

Patients hospitalized for a foreseeable duration of at least 24 hours will be offered participation in the longitudinal tab of the study, for which four non-injected MRI examinations will be performed. The examinations will be carried out remotely from the injected MRI (1h, 2h, 12h-15h, 24h-36h). These exams dedicated to research will include the following sequences for a maximum of 8 minutes:

* 3D T1 TFE 1.0 isotropic (2 minutes)
* 3D FLAIR (3 minutes)
* FABIR (3 minutes)

Conditions

  • MRI

Interventions

DEVICE

MRI with gadolinium injection

Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study. The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5.

Sponsors & Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

    lead NETWORK

Principal Investigators

  • julien savatovsky · Hôpital fondation Adolphe de Rothschild

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2023-06-16
Completion
2023-06-16

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04707170 on ClinicalTrials.gov